List of Excipients in Branded Drug ADAPALENE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Padagis Israel Pharmaceuticals Ltd	ADAPALENE	adapalene	45802-453	CARBOMER HOMOPOLYMER TYPE B
Padagis Israel Pharmaceuticals Ltd	ADAPALENE	adapalene	45802-453	CYCLOMETHICONE
Padagis Israel Pharmaceuticals Ltd	ADAPALENE	adapalene	45802-453	EDETATE DISODIUM
Padagis Israel Pharmaceuticals Ltd	ADAPALENE	adapalene	45802-453	GLYCERIN
Padagis Israel Pharmaceuticals Ltd	ADAPALENE	adapalene	45802-453	METHYLPARABEN

Generic Drugs Containing ADAPALENE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	adapalene	0093-6301	CARBOMER HOMOPOLYMER TYPE C
Teva Pharmaceuticals USA Inc	adapalene	0093-6301	EDETATE DISODIUM
Teva Pharmaceuticals USA Inc	adapalene	0093-6301	HYDROCHLORIC ACID
Teva Pharmaceuticals USA Inc	adapalene	0093-6301	METHYLPARABEN
Teva Pharmaceuticals USA Inc	adapalene	0093-6301	POLOXAMER 182

What are the Most Frequently-Used Excipients in ADAPALENE?

# Of NDCs	Excipient
1	ALCOHOL
1	CARBOMER 934
4	CARBOMER HOMOPOLYMER TYPE B
44	CARBOMER HOMOPOLYMER TYPE C
1	CARBOXYPOLYMETHYLENE

Excipient Strategy and Commercial Opportunities for Adapalene

Last updated: February 25, 2026

What is the current excipient formulation for adapalene?

Adapalene formulations typically include specific excipients to optimize stability, bioavailability, and patient compliance. Common excipients used in commercial products include:

• Retinoid-active base: Adapalene itself
• Carriers and stabilizers: Liquid paraffin, white soft paraffin, or petrolatum in topical gels or creams
• Humectants: Glycerin and purified water
• Emulsifiers: Polyethylene glycol derivatives in gel formulations
• Preservatives: Methylparaben, propylparaben
• Permeation enhancers: Limited use, but sometimes included to improve penetration

Manufacturers tailor excipients based on formulation type—gel, cream, or lotion—to optimize efficacy and patient adherence.

How do excipient choices influence formulation performance?

Excipients affect drug stability, shelf life, skin absorption, and patient tolerability:

• Stability: Liquid paraffin and petrolatum used in gels prevent oxidation and degradation of adapalene.
• Bioavailability: Emulsifiers enhance drug penetration through the stratum corneum.
• Patient compliance: Non-greasy, fast-drying formulations with minimal irritation boost adherence.
• Shelf life: Preservatives prevent microbial growth, extending product stability.

Formulation development balances these factors to meet regulatory standards and consumer preferences.

What are the commercial opportunities driven by excipient strategies?

1. Innovative formulations: Transition to novel delivery systems such as microemulsions or liposomes can enhance skin penetration and reduce irritation, creating premium product lines.

2. Excipient repurposing: Using excipients with intrinsic antimicrobial or anti-inflammatory properties can reduce the need for preservatives or adjunct ingredients, appealing to clean-label trends.

3. Customization for niche markets: Developing formulations tailored for sensitive skin, adolescents, or specific racial groups leverages excipient choices to address unique needs.

4. Patent extension: Novel excipient combinations or delivery systems can create new patent opportunities, extending market exclusivity.

5. Collaborations and licensing: Partnering with excipient suppliers that innovate bio-compatible or biodegradable excipients can differentiate products and open new markets.

Market Dynamics and Regulatory Considerations

• Global approvals: US FDA and EMA approve excipient compositions based on safety profiles and manufacturing processes.
• Development costs: R&D for novel excipient systems demands intensive stability testing and regulatory submission.
• Intellectual property: Patents on specific excipient formulations or delivery systems can garner licensing revenue or exclusivity.

Competitive Landscape

Major players such as Galderma (Differin), Teva, and Mylan optimize excipient strategies within their adapalene products. Focus areas include:

• Formulation stability
• Reduced irritation
• Enhanced penetration
• Ease of application

Small biotech firms with innovative excipient innovations target niche markets or seek licensing agreements.

Future Trends

• Increasing interest in biodegradable, plant-derived excipients
• Development of waterless, lotion-based formulations for convenience
• Use of nanotechnology-enabled excipients to improve delivery

Research is ongoing into bioactive excipients that can synergize with adapalene’s mechanism of action, offering potential drug-device combination opportunities.

---

Key Takeaways

• Excipient choices in adapalene formulations directly impact stability, delivery, tolerability, and patient compliance.
• Innovation in excipient technology can unlock premium product segments, extend patent life, and enable targeted market penetration.
• Regulatory pathways favor proven excipients, but novel combinations require extensive testing.
• Partnerships with excipient developers present avenues for differentiation and revenue growth.
• Emerging trends focus on sustainability and nanotechnology, for improved efficacy and consumer appeal.

---

FAQ

1. What excipients are most common in adapalene gels?
Liquid paraffin, carbomers, preservatives like methylparaben, and humectants such as glycerin are frequently used.

2. How do excipients affect adapalene’s stability?
Excipients like petrolatum provide a barrier to oxidation, protecting adapalene from degradation.

3. Are there opportunities to develop preservative-free adapalene formulations?
Yes, using antimicrobial excipients like sorbic acid or physical preservation methods can support preservative-free options.

4. Can new excipients improve patient tolerability?
Yes, excipients that minimize irritation or improve moisturizing can enhance tolerability, especially in sensitive skin.

5. What regulatory hurdles exist for excipient innovation?
New excipients or delivery systems require safety testing, stability data, and regulatory review, which can extend time-to-market.

---

References

1. U.S. Food and Drug Administration. (2021). Guidance for Industry – Topical Drug Products.
2. European Medicines Agency. (2022). Guideline on excipients in the product information of human medicinal products.
3. Chen, Q., et al. (2020). Advances in topical delivery systems for adapalene. Journal of Controlled Release, 324, 643-652.
4. Patel, R., et al. (2019). Excipient strategies for enhancing topical drug penetration. International Journal of Pharmaceutics, 567, 118455.
5. Singh, A., et al. (2022). Sustainable excipients in pharmaceutical formulations: A review. Pharmaceutical Development and Technology, 27(1), 1-15.